New Horizons of Biomarkers in Metastatic Thyroid Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2025 Jan 2

PMID 39744583

Authors

Alicia Sanchez Cendra

Leonel Pekarek

Beatriz Iglesias Pedrejon

Loreto Bernier

Eduardo David Roberts Cervantes

Cristina Sanchez Cendra

Javier Cassinello

Laura Lopez-Gonzalez

Felix Manez

Concepcion Blanco Carrero

Clara Tasende Fernandez

Tomas Ratia Gimenez

Diego Martin Cordova Garcia

Alberto Gutierrez-Calvo

Melchor Alvarez-Mon

Raul Diaz-Pedrero

Miguel A Ortega

Affiliations

Soon will be listed here.

Abstract

This review focuses on the latest advancements in using biomarkers to diagnose, predict outcomes, and guide the treatment of different types of thyroid cancer, such as anaplastic, papillary, medullary, and follicular thyroid carcinoma. We highlight the key role of both traditional and new biomarkers in improving the treatment of these cancers. For anaplastic thyroid cancer, biomarkers are crucial for detecting distant metastases and making treatment decisions. In papillary thyroid carcinoma, biomarkers are used to predict patient survival, taking into account factors like age, the presence of metastasis, and the extent of the tumor. Medullary thyroid carcinoma has seen advancements due to genetic research, particularly in identifying RET mutations, which help in selecting targeted treatments. In follicular thyroid carcinoma, understanding the tumor's molecular profile is important for assessing its aggressiveness and potential to spread. The review also discusses the therapeutic use and variability of various biomarkers in advanced thyroid cancers. Among the most relevant innovations are advancements in detection techniques such as the detection of circulating tumor DNA (ctDNA) and microRNA is emerging as a promising tool for monitoring the disease and predicting treatment response. The integration of these biomarkers into clinical practice, including the most recent detection techniques, is a significant step toward personalized medicine, leading to more accurate diagnoses and better outcomes for thyroid cancer patients.

References

Abdullah M, Mat Junit S, Ng K, Jayapalan J, Karikalan B, Hashim O . Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations. Int J Med Sci. 2019; 16(3):450-460. PMC: 6428975. DOI: 10.7150/ijms.29935. View

Jiang K, Li G, Chen W, Song L, Wei T, Li Z . Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas. Onco Targets Ther. 2020; 13:1311-1319. PMC: 7025673. DOI: 10.2147/OTT.S231361. View

Prasad M, Pellegata N, Huang Y, Nagaraja H, de la Chapelle A, Kloos R . Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2004; 18(1):48-57. DOI: 10.1038/modpathol.3800235. View

Nana-Sinkam S, Croce C . MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. Genome Biol. 2014; 15(9):445. PMC: 4709998. DOI: 10.1186/s13059-014-0445-8. View

Ng T, Gunda V, Li R, Prytyskach M, Iwamoto Y, Kohler R . Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer. Radiology. 2020; 298(1):123-132. PMC: 7771993. DOI: 10.1148/radiol.2020201791. View

Suzuki A, Hirokawa M, Takada N, Higuchi M, Yamao N, Kuma S . Diagnostic significance of PAX8 in thyroid squamous cell carcinoma. Endocr J. 2015; 62(11):991-5. DOI: 10.1507/endocrj.EJ15-0226. View

Qiu Z, Wei W, Sun Z, Shen C, Song H, Zhang X . Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer. Cell Physiol Biochem. 2018; 48(2):718-730. DOI: 10.1159/000491898. View

Mitchell A, Gandhi A, Scott-Coombes D, Perros P . Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S150-S160. PMC: 4873931. DOI: 10.1017/S0022215116000578. View

Ardizzone A, Calabrese G, Campolo M, Filippone A, Giuffrida D, Esposito F . Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis. Int J Mol Sci. 2021; 22(9). PMC: 8125123. DOI: 10.3390/ijms22094697. View

10.

Giuffrida D, Gharib H . Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000; 11(9):1083-9. DOI: 10.1023/a:1008322002520. View

11.

Bergholm U, Adami H, Auer G, Bergstrom R, Backdahl M, Grimelius L . Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. A nationwide study in Sweden. The Swedish MTC Study Group. Cancer. 1989; 64(1):135-42. DOI: 10.1002/1097-0142(19890701)64:1<135::aid-cncr2820640123>3.0.co;2-g. View

12.

Harris P, Bible K . Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs. 2011; 20(10):1357-75. PMC: 3195511. DOI: 10.1517/13543784.2011.614230. View

13.

Araque K, Gubbi S, Klubo-Gwiezdzinska J . Updates on the Management of Thyroid Cancer. Horm Metab Res. 2020; 52(8):562-577. PMC: 7415555. DOI: 10.1055/a-1089-7870. View

14.

Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V . TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol. 2015; 172(4):403-13. DOI: 10.1530/EJE-14-0837. View

15.

Nechifor-Boila A, Catana R, Loghin A, Radu T, Borda A . Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Rom J Morphol Embryol. 2014; 55(1):49-56. View

16.

Johnson W, Patel P, Hernandez A, Grandinetti L, Huen A, Marks S . Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation. J Cutan Pathol. 2015; 43(3):270-5. DOI: 10.1111/cup.12636. View

17.

Allin D, Shaikh R, Carter P, Thway K, Sharabiani M, Gonzales-de-Castro D . Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. Eur J Cancer. 2018; 103:165-175. DOI: 10.1016/j.ejca.2018.08.013. View

18.

Chiu C, Strugnell S, Griffith O, Jones S, Gown A, Walker B . Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol. 2010; 176(5):2067-81. PMC: 2861072. DOI: 10.2353/ajpath.2010.090353. View

19.

Eszlinger M, Stewardson P, McIntyre J, Box A, Khalil M, Hyrcza M . Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers. Eur Thyroid J. 2022; 11(1). PMC: 9142806. DOI: 10.1530/ETJ-21-0061. View

20.

Hsiao S, Zehir A, Sireci A, Aisner D . Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy. J Mol Diagn. 2019; 21(4):553-571. PMC: 7456740. DOI: 10.1016/j.jmoldx.2019.03.008. View